Iron is crucial for various life activities of cells (11). An imbalance in the iron redox reaction and the iron ion cycle in cells are important factors leading to ferroptosis in cells (12). Extracellular iron enters the cell by binding to transferrin (TF), which recognizes transferrin receptor 1 (TFR1) on the cell membrane (13). Within the cell, iron is reduced to its divalent form by the six-transmembrane epithelial antigen of the prostate 3 (STEAP3) and is then translocated into the cytoplasm by divalent metal transporter 1 (DMT1) ( Figure 1 ) (14, 15). Intracellular iron is stored either as ferritin or in the labile iron pool (LIP). Iron subsequently exits the cell into the extracellular environment through the iron transport protein ferroportin (FPN) (16, 17).

Excessive free iron leads to iron accumulation, which triggers nonenzymatic, iron-dependent Fenton chain reactions that directly produce excessive reactive oxygen species, thereby causing oxidative damage to cells (18). Therefore, excessive iron accumulation promotes ferroptosis in cells. IRP1 and IRP2 are crucial proteins involved in the meticulous regulation of intracellular iron levels. These proteins play significant roles in managing the iron cycle within the cell by engaging in posttranscriptional regulation. This process specifically targets genes that are associated with iron transport inside the cell, ensuring that iron homeostasis is effectively and efficiently maintained (19, 20). Through their regulatory activities, IRP1 and IRP2 help control the availability of iron, which is essential for various cellular functions and overall cellular health. Ferritin, which is composed of a light chain (FTL) and a heavy chain (FTH), has significant antiferroptotic properties. The degradation of ferritin via lysosome-associated ferritin-induced autophagy leads to elevated levels of free reactive iron within cells and an accumulation of iron, which ultimately results in iron-induced cellular death (21, 22). Suppressing ferritin-induced autophagy triggered by nuclear receptor coactivator 4 (NCOA4) promotes the effective use of cellular iron ions, thus reducing the occurrence of cellular ferroptosis ( Figure 1 ).

Poly (RC)-binding proteins (PCBPs), which are iron chaperones that transfer iron to corresponding proteins- can transport Fe²⁺ to ferritin, thereby increasing ferroptosis resistance in hepatocytes (23). Haem oxygenase 1 (HO-1) facilitates the breakdown of heme, resulting in increased levels of reactive iron ions within the cell, which play a role in inducing cellular iron-related death. Notably, HO-1 has both positive and negative regulatory effects on ferroptosis (24, 25). ATM, a serine–threonine protein kinase, can block metal - regulated transcription factor 1 (MTF1), thereby promoting ferroptosis (26). Furthermore, prominin 2 (PROM2) reduces ferroptosis in breast cancer cells by promoting the export of iron from these cells (27).

Moderate levels of cellular iron are essential for maintaining normal bone health. Bone remodeling and resorption during physiological processes require adequate amounts of iron. Abnormal iron metabolism plays a significant role in various diseases. In the pathology of OA, cellular iron overload can increase localized inflammatory mediators, contributing to OA development (28). Additionally, abnormal iron metabolism can impair osteoclast function and induce oxidative stress, leading to an imbalance in bone homeostasis and bone loss, which is associated with OP formation (29, 30). Iron overload in chondrocytes can elevate markers of chondrocyte catabolism, triggering cartilage degeneration. Furthermore, iron overload in synoviocytes can influence cytokine expression, resulting in synovial inflammation linked to OA formation (28, 31). Therefore, iron metabolism in the bone microenvironment significantly impacts both physiological processes and the pathological development of bone.

A disruption of cell membrane integrity, which can lead to cell death, represents one potential mechanism through which ferroptosis occurs. Polyunsaturated fatty acids (PUFAs) play a critical role as key constituents of the cytoplasmic membrane and act as major targets of ROS (32–34). As a result, managing lipid metabolism is essential to the regulatory processes related to ferroptotic cell death. The enzyme adenylate-activated protein kinase (AMPK), which acts as a sensor of cellular energy levels, influences ferroptosis by facilitating the phosphorylation of acetyl coenzyme A carboxylase (ACC) and the production of polyunsaturated fatty acids (35). Additionally, the dissection of its upstream kinase, liver kinase B1 (LKB1), increases the sensitivity of mouse embryonic fibroblasts to ferroptosis (36).

In the process of ferroptosis, PUFAs serve as major targets for lipid peroxidation. Research has shown that oleic acid can effectively prevent erastin-triggered ferroptosis by engaging in competition with PUFAs to be incorporated into PLs (37). PUFAs can be integrated into cellular membranes via acylcarnitine synthase 4 (ACSL4) (38) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) (39), increasing cellular vulnerability to ferroptosis. The oxidation of unsaturated fatty acids may proceed through both enzymatic and nonenzymatic mechanisms. For example, arachidonic acid (AA) is converted by ACSL4 and LPCAT3. Subsequently, the resultant molecule undergoes oxidation through either lipoxygenase (Lox) or a non-enzymatic pathway, leading to the formation of PE-AA-OOH ( Figure 1 ) (40, 41).

Significant lipid peroxidation plays a crucial role in ferroptosis, potentially resulting in cellular death via various mechanisms. These mechanisms involve modifications to the membrane’s lipid bilayer structure, the creation of membrane pores that impair barrier function, a decrease in membrane thickness, and alterations in permeability (42). Furthermore, peroxidated lipids can be decomposed into toxic derivatives, which may induce significant cytotoxicity (43, 44).

Lipid peroxidation serves as a crucial mechanism in ferroptosis, and its occurrence within the bone microenvironment significantly contributes to cellular ferroptosis, thereby impacting bone health. Inhibiting lipid peroxidation in bone microenvironment cells may represent a promising therapeutic approach for treating bone-related diseases. Notably, the inhibition of ACSL4 has been shown to reduce the incidence of neuronal ferroptosis, indicating that ACSL4 could be a viable target for the treatment of bone-related disorders (45). Furthermore, compounds that inhibit the lipid peroxidation process, such as baicalein and zileuton, have demonstrated the ability to enhance bone density by promoting bone formation, suggesting that these agents may serve as potential therapeutic options for OP (46).

System X_C ^–GSH–GPX4 pathway is an important antioxidant pathway in cells. Glutathione peroxidase 4 (GPX4) is a key enzyme characterized by the presence of selenocysteine, which plays a vital role in neutralizing phospholipid hydroperoxides (47). Research has shown that when GPX4 is absent, lipid peroxidation leads to non-apoptotic cell death in mouse embryonic fibroblasts (48). Both the expression levels and functionality of GPX4 are influenced by selenium and glutathione (GSH). Selenium participates in the process of GPX4 synthesis and substitutes for the sulfur in cysteine (49). Furthermore, selenium can also induce the upregulation of GPX4 expression through the transcriptional pathway to reduce ferroptosis (50).

GPX4 exerts its physiological functions through GSH. During the process of phospholipid hydroperoxide being reduced to the corresponding phospholipid alcohols, GSH acts as an electron donor, while glutathione disulfide (GSSG) is produced simultaneously (51). Glutathione disulfide reductase (GSR) can recycle oxidized glutathione using electrons sourced from reduced NADPH to restore glutathione ( Figure 1 ) (52).

In the cytoplasm, GSH is synthesized through the catalytic action of glutamate cysteine ligase (GCL) and glutathione synthetase (GSS) (52). In this synthesis reaction, cysteine serves as the critical rate-limiting factor (53). Cysteine enters cells in its oxidized form, known as cystine, through System X_C ^-. Once inside the cell, cystine is reduced to cysteine by the enzyme thioredoxin reductase 1 (TXNRD1) ( Figure 1 ) (54). Furthermore, cysteine may also be synthesized from methionine via the transsulfuration pathway (55). The reverse transporter protein System X_C ^-, which operates as a heterodimeric complex of SLC7A11 and SLC3A2, enables the exchange of cystine and glutamate across the plasma membrane (3, 56). P53 can induce ferroptosis and consequently tumor cell death by inhibiting GSH synthesis through the downregulation of SLC7A11 expression (57). Erastin can directly inhibit cystine uptake, leading to ferroptosis, whereas RSL3 can inhibit GPX4 to induce ferroptosis ( Figure 1 ) (58).

Ferroptosis inhibitory protein 1 (FSP1) serves as an important antioxidant involved in the mechanism of ferroptosis (59). By utilizing NADPH, FSP1 reduces coenzyme Q to ubiquinol, effectively halting lipid autoxidation ( Figure 1 ) (60, 61). Moreover, FSP1 can inhibit cell death through α-tocopherol-mediated antioxidation, which is more potent than the former mechanism (62). The antioxidant effects of the FSP1 pathway are primarily mediated by coenzyme Q10 (CoQ10), an isoprenoid benzoquinone compound (63, 64). Additionally, panthenol (CoQ10H2), serves as an important antioxidant that targets free radicals. It exerts its antiferroptotic effect by directly scavenging lipid peroxidation-inducing free radicals (65).

CoQ10 can be synthesized by the mevalonate (MVA) pathway using acetyl coenzyme A (66). Supplementation with farnesyl pyrophosphate, a product of CoQ10 synthesis, has been shown to inhibit ferroptosis induced by FIN56 (67), highlighting the endogenous inhibitory role of CoQ10 in this process. In addition to its redox enzyme function, FSP1 also has a membrane repair function. It can suppress ferroptosis by triggering the ESCRT-III pathway for membrane repair (55, 68). These findings suggest that FSP1 cannot protect against ferroptosis triggered by the deletion of GPX4. This finding indicates that the NADPH–FSP1–CoQ10 pathway is a separate and parallel system. It functions in conjunction with GPX4 and GSH to inhibit lipid ROS and ferroptosis (60, 61).

Tetrahydrobiopterin (BH4) possesses robust antioxidant properties, enabling it to directly curb lipid peroxidation (69, 70). Additionally, BH4 participates in coenzyme Q10 synthesis, shielding cells from ferroptosis ( Figure 1 ). In addition, BH4 functions as a cofactor for several key enzymes related to dopamine and NO production. Research has demonstrated that both dopamine and NO are associated with ferroptosis (71).

In the synthesis of BH4, GTP cyclohydrolase 1 (GCH1) serves as the key regulatory enzyme, thereby determining the level of BH4 ( Figure 1 ). Moreover, BH4 can be regenerated by dihydrofolate reductase (DHFR). BH4 inhibits ferroptosis by selectively preventing the depletion of phospholipids from two polyunsaturated fatty acid tails (69). A previous study confirmed that dopamine can inhibit ferroptosis induced by erastin (72) and that BH4 is an auxiliary factor for the key enzyme that regulates dopamine synthesis. Additionally, a positive correlation was observed between the expression of GCH1 and the levels of BH4 in cells. Elevated intracellular levels of BH4 inhibit lipid peroxidation and prevent cellular ferroptosis. GCH1, independent of the GPX4 antioxidant pathway, primarily enhances the antioxidant activity of cells by promoting BH4 production and thus protects cells from ferroptosis. The GCH1–BH4–DHFR pathway clearly serves as a key regulatory pathway for ferroptosis. Furthermore, other antioxidant agents, such as vitamin E (73), thioredoxin (74), and aldehyde–ketone reductase family 1, also play certain roles in ferroptosis (75).

Dihydroorotic acid dehydrogenase (DHODH) is a mitochondrial enzyme that contains iron and depends on flavin; it is located in the inner membrane of mitochondria. The primary role of this enzyme is to facilitate the fourth step in pyrimidine synthesis by converting dihydroorotate (DHO) into orotate ( Figure 1 ). At the same time, it reduces ubiquinone to dihydroubiquinone via electron transfer across the mitochondrial inner membrane (76). CoQH2 acts as an antioxidant that traps free radicals, thereby inhibiting lipid peroxidation at the inner mitochondrial membrane and ultimately preventing iron-induced cell death ( Figure 1 ) (77).

An experimental analysis of a group of cancer cell lines with low and high GPX4 expression demonstrated that inhibiting DHODH could induce ferroptosis in tumor cells with low GPX4 expression while enhancing ferroptosis resistance in cancer cells with high GPX4 expression. The DHODH–CoQH2 pathway functions as an antioxidant pathway that works independently of the GPX4 system, providing an antiferroptotic effect by preventing mitochondrial lipid peroxidation (77, 78).

The antioxidant system of cells serves as a critical defense mechanism against ferroptosis. Research has demonstrated that decreased levels of GPX4 and SLC7A11 in the bone tissue of mice with OP correlate with increased bone mineral density and improved bone quality upon elevation of glutathione levels (79). Furthermore, reduced GPX4 levels in chondrocytes heighten their susceptibility to ferroptosis, adversely impacting normal cartilage function (80). These findings suggest that ferroptosis, induced by an imbalance in the antioxidant system, may significantly influence bone health. Consequently, targeting ferroptosis through the activation of the cellular antioxidant system represents a promising avenue for intervention in bone diseases. Furthermore, inducing ferroptosis by inhibiting the cellular antioxidant system presents a potential therapeutic strategy for OS, as various anticancer agents exert their effects by targeting antioxidant system-related proteins such as GPX4 (57).

Normal iron cycling in cells plays an important regulatory role in maintaining bone health (82). Osteoblasts form bone tissue, while osteoclasts absorb it. The two work in concert in bone formation and remodeling. Increasing evidence suggests that disturbances in iron metabolism can negatively influence the formation and functions of osteoblasts and osteoclasts, thereby disrupting the balance between osteogenesis and bone resorption. Consequently, maintaining iron homeostasis is vital for optimal bone growth and development (83).

During osteoclast differentiation, the demand for iron increases, and the expression of TFR1 is increased through posttranscriptional regulation, thereby increasing iron uptake by the cell. These findings demonstrate the positive regulatory effect of TFR1 on osteoclasts (84). FPN regulates cellular iron efflux (16, 17) and inhibits osteoclast maturation through pathways such as the JNK pathway. During the initial stages of osteoclast maturation, a reduction in the transcription of FPN promotes osteoclast differentiation (85). A study showed that increased plasma iron levels in FPN mutant mice led to decreased osteogenesis, indicating a negative regulatory role of ferroportin in osteoclasts (86, 87).

Osteoclasts, which are specialized cells responsible for bone resorption, arise from the differentiation of myeloid progenitor cells found in the bone marrow (88). The signaling pathway involving receptor activator of nuclear factor-κB ligand (RANKL), its receptor (RANK), and osteoprotegerin (OPG) plays a pivotal role in the regulation of bone resorption. This pathway is essential because it modulates the differentiation and activation of osteoclasts, thereby influencing the overall process of bone resorption (89, 90). Through this intricate signaling mechanism, the balance of bone remodeling is maintained, highlighting the importance of regulating iron levels to ensure optimal bone health.

Osteoclasts require substantial amounts of mitochondrial energy to perform their physiological functions, and iron ions are crucial for mitochondrial synthesis. Iron ion uptake mediated by TFR1 plays a significant regulatory role in osteoclast differentiation (91, 92). It regulates osteoclasts and mitochondria through the activation of the Src–Rac1–WAVE regulatory complex pathway, which in turn modulates mitochondrial respiration (93).

When iron levels are excessively high, the RANKL/OPG ratio increases, leading to the promotion of osteoclast maturation and bone resorption through TFR1-mediated iron uptake ( Figure 2 ). Conversely, iron-chelated lactoferrin inhibits osteoclast-mediated bone resorption by reducing the RANKL/OPG ratio, thereby increasing the bone mineral density (92, 94). TFR1-mediated iron uptake mainly regulates the growth and development of mature osteoclasts, but its impact on osteoclast precursors is relatively limited (93). These findings suggest that iron overload might lead to bone loss by promoting the activity and function of osteoclasts (95, 96).

Osteoblasts, which are essential for bone development, arise from mesenchymal progenitor cells that are vital for managing the processes of bone creation and remodeling (97). Iron primarily exerts its influence by inhibiting the expression of alkaline phosphatase (ALP) and the mineralization of osteoblasts. Notably, trivalent iron has a more pronounced inhibitory effect than does divalent iron (98). Alkaline phosphatase is one of the key factors regulating the mineralization of osteoblasts. The decrease in ALP activity could strengthen the inhibitory effects of Fe³⁺ and Fe²⁺ on osteoblasts.

Iron hinders the function of osteoblasts by reducing the expression levels of markers associated with osteogenic differentiation in both C2C12 myoblasts and bone marrow-derived mesenchymal stem cells (BM-MSCs) (99, 100). These findings indicate that iron has a greater inhibitory effect on osteoblast precursors than on mature osteoblasts during osteogenic induction, which is similar to the regulation of osteoclasts by TFR1. Excessive iron accumulation may suppress the function and osteogenic differentiation of osteoblasts. Research has indicated that when iron ions are present at specific concentrations, they can inhibit the activity of Runt-related transcription factor 2 (Runx2), a critical regulator of osteoblast differentiation ( Figure 2 ). This inhibition results in reduced expression of key osteogenic markers, such as alkaline phosphatase (ALP) and osteocalcin, which are essential for the proper differentiation of bone marrow-derived mesenchymal stem cells (BM-MSCs). Moreover, the excessive accumulation of intracellular iron ions further contributes to the downregulation of the osteoblast phenotype, which is essential for maintaining healthy bone formation (101). Thus, iron overload is inferred to cause bone damage by promoting osteoclast activity while simultaneously suppressing the formation of osteoblasts.

Neutrophils are intricate cells with many specialized functions that are vital for managing different pathophysiological processes. Serving as effector cells in the innate immune response, these cells represent the most abundant type of immune cells among human white blood cells. The primary bactericidal role of neutrophils is accomplished via phagocytosis and the creation of neutrophil extracellular traps (NETs), which are composed of degraded chromatin and granular proteins from within the cell, triggered by various stimuli. Even after the death of neutrophils, NETs can still perform their bactericidal function.

Ferroptosis may be involved in the formation of NETs and the regulation of neutrophil recruitment (102). The ferroptosis inhibitor sulfasalazine (SSZ) enhances ferroptosis by blocking SLC7A11 and stimulating the lipoxygenase ALOX ( Figure 2 ) (103). Research indicates that ether-bonded glycerolipids increase cellular sensitivity to ferroptosis, whereas ether lipids are crucial for the formation of the extracellular meshwork induced by sulfasalazine (104). This result suggests a potential association between these two phenomena. Furthermore, ferroptosis is related not only to NETs but also to autoimmune diseases associated with neutrophils. Nevertheless, the impact of neutrophil ferroptosis on the progression of these diseases has yet to be completely verified.

Macrophages stem from monocytes and can be divided into two types: M1 and M2. They contribute to both innate and adaptive immunity in vertebrates. Phagocytes primarily function in phagocytosis, which involves the engulfment and digestion of cell debris and pathogens, either as fixed or free-floating cells.

Macrophages are closely associated with ferroptosis. Ferroptotic and M1-type macrophages both exhibit iron accumulation. Excess iron may promote the polarization of macrophages towards the M1 phenotype ( Figure 2 ). In terms of cytokines, macrophages cause inflammation by releasing proinflammatory factors. Similarly, an increase in the levels of proinflammatory factors also occurs within ferroptotic cells. By releasing cytokines, macrophages can regulate the activity of Lox, thereby inducing ferroptosis. Inducible nitric oxide synthase (iNOS) plays a crucial role in M1 macrophages by negatively regulating ferroptosis ( Figure 2 ) (105). An impairment of the GPX4 system in M2-type macrophages can lead to cellular ferroptosis (106). Macrophages are capable of generating ROS, which in turn can drive their differentiation into M1-type macrophages (107, 108). IL-6 secreted by macrophages promotes hepcidin transcription via the activation of the JAK-STAT3 signaling pathway ( Figure 2 ). Furthermore, macrophages secrete IL-1β to upregulate hepcidin expression. These combined actions result in decreased levels of FPN expression, causing an accumulation of intracellular iron and eventually resulting in iron-induced cell death (109, 110).

Lymphocytes represent the smallest category of white blood cells. They are essential for the body’s immune response. These cells can be divided into three primary types according to their functions: T cells, B cells, and natural killer (NK) cells.

Maintaining proper iron balance within cells is essential for T-cell survival and the performance of their typical physiological roles (111). Elevated levels of ROS and iron in haematopoietic cells lacking the H-ferritin gene lead to a reduction in T-cell populations ( Figure 2 ) (112). T cells deficient in GPX4 undergo ferroptosis, which results in compromised immune function (113). Research has shown that antioxidant interventions, including vitamin E, deferoxamine (DFO), or Fer-1, can alleviate ferroptosis in T cells lacking GPX4 ( Figure 2 ) (114). Additionally, antibodies produced by B cells can influence iron-induced cell death, while ROS also impact the B-cell quantity and normal function (115, 116). Lipid peroxidation induced by the ferroptosis inducer erastin increases the proliferation of human peripheral blood mononuclear cells (PBMCs) and their differentiation into B cells and NKs (116).

BMSCs that differentiate into osteoblasts or chondrocytes are crucial for the development, reconstruction, and tissue regeneration of bone and cartilage. Iron homeostasis is of vital importance for their proliferation and differentiation.

Studies have confirmed that iron homeostasis imbalance severely damages the bone marrow microenvironment of mice, leading to bone destruction (117). Excessive iron can also trigger oxidative stress, leading to trabecular bone damage and bone loss. Antioxidants can inhibit the formation of osteoclasts and thereby alleviate this process (30). Furthermore, the accumulation of iron in synoviocytes disrupts the balance of various inflammatory factors in the joint, impairing the normal physiological function of cartilage. It increases the capacity of monocytes and synovial fibroblasts within the joint to absorb iron. This process accelerates the connective tissue degradation mediated by histone proteases and consequently induces joint disease (31, 118).

Osteoblasts form bone, and osteoclasts absorb bone. The two work in concert to maintain normal bone metabolism. Osteoporosis is a systemic disease characterized by a decreased bone density, destruction of the bone microstructure, and increased bone fragility (119). Osteoporosis can be divided into primary osteoporosis (POP) and secondary osteoporosis (120). Osteoporosis causes an increase in bone fragility, often leading to fractures in elderly and postmenopausal women (121, 122). Statistical data indicate that approximately thirty-three percent of older females and twenty percent of older males are affected (123).

Disrupted calcium metabolism may lead to osteoporosis, and an increasing body of research indicates a potential link between iron-induced cell death and osteoporosis (124). Intracellular iron overload not only inhibits osteoblast function but also enhances osteoclast activity, thereby contributing to osteoporosis. A significant amount of research has indicated that individuals with anaemia frequently experience osteoporosis as well (125, 126), which may be related to iron overload-mediated ferroptosis caused by long-term blood transfusions in anaemia patients (127), and their fracture risk is associated with the frequency of blood transfusions (128). Furthermore, research has revealed a link between haemochromatosis and osteoporosis. In individuals with haemochromatosis, osteoporosis is linked to iron overload (129), and ferroptosis might be the primary factor driving osteoporosis in these populations (130).

Elevated concentrations of reactive iron ions in osteoblasts and osteoclasts result in cellular iron toxicity. With the ongoing accumulation of intracellular iron ions, a notable increase in the levels of iron cycling phase proteins, including DMT1 and TFR1, occur within both osteoblasts and osteoclasts (131, 132). Consequently, iron overload-mediated ferroptosis contributes to the development of osteoporosis through its detrimental effects on osteoblasts, osteoclasts, and BM-MSCs, ultimately disrupting bone homeostasis.

Osteoporosis is a prevalent complication of type II diabetes mellitus, with studies confirming a strong link between iron-mediated cell death and glucose metabolism. Increased serum ferritin levels have been observed in diabetic mice with osteoporosis, accompanied by significantly reduced levels of SLC7A11 and GPX4 in bone tissue (133). High glucose levels are capable of decreasing osteocalcin expression, reducing alkaline phosphatase activity, and suppressing bone mineralization (134, 135). Research has shown that the expression of HO-1 in osteocytes in a high-glucose microenvironment increases. HO-1 facilitates the breakdown of heme, resulting in the release of significant quantities of reactive iron ions, which then promote the Fenton reaction, ultimately producing lipid peroxides and causing ferroptosis in osteoblasts ( Figure 3 ) (124, 136). This process suggests that HO-1 might serve as a potential therapeutic target for treating diabetic osteoporosis.

Ferroptosis is distinct from apoptosis; however, these two modes of cell death are not entirely independent in the pathological progression of OP. The cytokines involved in both processes interact with one another, contributing to the development of OP. Research has demonstrated that among the pathogenic factors associated with osteoporosis, advanced glycosylation end products can induce both ferroptosis and apoptosis in osteoblasts, ultimately leading to OP. Furthermore, DFO has been shown to inhibit this process (137). These findings suggest that targeting the shared key factors of apoptosis and ferroptosis may provide a more effective approach for the treatment of OP.

Mitoferritin located in mitochondria can reduce free iron in mitochondria and thereby decrease the sensitivity of cells to ferroptosis. The overexpression of mitochondrial ferritin has been shown to inhibit oxidative stress, which in turn mitigates ferroptosis (138). In contrast, decreased expression of mitochondrial ferritin can initiate mitochondrial autophagy through the ROS/PINK1/Parkin pathway, leading to the accumulation of ferritin and the enhancement of ferroptosis in osteoblasts ( Figure 3 ) (135). These results suggest that mitochondrial ferritin could represent a promising future avenue for treating diabetic osteoporosis. Based on these findings, iron-induced cell death in osteoblasts is significantly involved in the progression of osteoporosis. Additionally, the pathway associated with iron-mediated death in osteoblasts, which utilizes various mechanisms, may represent a potential approach for the clinical management of osteoporosis.

Research on ferroptosis in OP is on the rise; however, the epigenetic regulatory mechanisms involved remain under investigation. It has been proposed that METTL14-mediated m6A modification plays a crucial role in the expression of GPX4. This indicates that the regulation of ferroptosis in osteoporosis via m6A modification may represent a promising avenue for future treatment strategies for OP (139).

Osteoarthritis is a degenerative condition of the joints characterized by the breakdown of cartilage, inflammation of the synovium, and changes in the subchondral bone structure (140, 141). Factors such as age, oestrogen levels, and mechanical stress play roles in increasing the likelihood of developing this disease (142–144). Osteoarthritis is characterized mainly by joint pain, deformity and functional impairment (145, 146). Additionally, it substantially increases the risks of cardiovascular incidents and overall mortality (147, 148). Currently, the number of OA patients worldwide exceeds 300 million (149).

Recent research has demonstrated a significant link between ferroptosis and OA, suggesting that this form of cell death might exacerbate the pathological mechanisms associated with OA (150, 151). Furthermore, the inhibition of ferroptosis represents a novel therapeutic target for OA management (152, 153). Iron overload has been observed in OA patients. Iron overload affects the progression of OA. From an imaging perspective, increased ferritin levels can exacerbate the severity of osteoarthritis (154, 155). Additionally, a positive correlation has been observed between serum iron levels and transferrin saturation and the progression of OA (156). A study conducted on guinea pigs susceptible to osteoporosis, which were placed on a diet low in iron, revealed that lower systemic iron levels delayed the development of cartilage damage. In contrast, when exogenous iron was administered, these animals developed knee osteoarthritis (157). These results highlight the significant impact of iron overload, stemming from iron dysregulation, on the development of OA.

Chondrocytes are involved in maintaining the integrity of the extracellular matrix and controlling the balance of articular cartilage homeostasis, thereby contributing to the deceleration of OA development (158, 159). In the pathological process of OA, cartilage degeneration is a key event. Research has shown that ferroptosis of chondrocytes exacerbates the progression of OA pathology. Both the induction of an inflammatory environment and a redox system imbalance promote ferroptosis in chondrocytes (160). Interleukin-1β (IL-1β), a factor that mimics an inflammatory condition, is capable of triggering alterations in the ROS concentrations within chondrocytes. It also enhances the accumulation of lipid peroxides and alters proteins associated with ferroptosis, such as GPX4, which ultimately result in the ferroptosis of chondrocytes (80, 160). Ferroptosis in chondrocytes increases the levels of MMP13 and IL-1β, simultaneously reducing the expression of type II collagen. This alteration in the balance of the extracellular matrix plays a role in the progression of OA ( Figure 4 ).

Fer-1 activates the Nrf2 antioxidant system, leading to elevated GPX4 levels and increased type II collagen production in chondrocytes. Additionally, Fer-1 mitigates the alterations in ferroptosis-related protein expression induced by IL-1β (160). In an inflammatory setting induced by IL-1β, increased levels of hypoxia-inducible factor-2α (HIF-2α) coupled with diminished GPX4 expression in chondrocytes increase their susceptibility to ferroptosis ( Figure 4 ) (80, 161). Antioxidant and anti-inflammatory substances, such as D-mannose, icaritin (162) and Fer-1, inhibit ferroptosis in chondrocytes by regulating the GPX4 pathway, thereby slowing cartilage degeneration and decelerating the pathological process of OA (80, 163).

Furthermore, subchondral bone is crucial for maintaining normal joint function. Ferroptosis may promote osteoclast bone resorption by inhibiting osteoblast function, thereby affecting the homeostasis and structural integrity of subchondral bone and leading to the occurrence of osteoarthritis (164, 165). Synovial inflammation promotes osteoarthritis. The synovium can secrete proinflammatory cytokines, leading to cartilage damage. Research has shown that excessive iron accumulation occurs in the synovium in haemophilic arthropathy, resulting in synovitis (150, 166). During the development of osteoarthritis, the synovium undergoes interstitial vascularization, fibrosis and hyperplasia (167), and macrophages and fibroblasts in the synovium can release proinflammatory cytokines, etc., which cause synovitis and cartilage degeneration.

RNA LINC00618 promotes apoptosis by increasing the levels of the pro-apoptotic protein, cleaved caspase-3, and also induces ferroptosis by inhibiting the cellular antioxidant system, suggesting a potential interaction between apoptosis and ferroptosis (168). Furthermore, cellular pyroptosis contributes to the progression of bone diseases. In the context of OA, the inflammatory response triggered by cellular pyroptosis exacerbates cartilage degeneration and synovial inflammation, thereby accelerating OA progression (169). These findings suggest that there may be mutual regulation between ferroptosis and other forms of cell death, warranting further investigation into the molecular interaction mechanisms to explore their potential clinical significance.

Epigenetic modifications play a crucial role in regulating ferroptosis in chondrocytes. The histone methyltransferase NSD1 has been identified as having potential therapeutic value by upregulating the H3K36me2 modification, thereby activating the expression of the transcription factor SOX9, which subsequently downregulates the key enzyme for ferroptosis, ACSL4, thus attenuating chondrocyte ferroptosis (170). Furthermore, the lactate metabolizing enzyme LDHB promotes H3K18 histone lactoylation, enhances ACSL4 expression, and induces chondrocyte ferroptosis, representing another epigenetic regulatory target for OA (171).

One of the most common reasons for chronic low back pain is lumbar disc herniation. After degenerative changes occur in the disc, the annulus fibrosus can break, leading to the protrusion or bulging of the nucleus pulposus, either independently or in conjunction with the annulus fibrosus and the cartilaginous plate. This condition can irritate or compress the spinal nerve roots, resulting in low back pain (172, 173).

Lumbar intervertebral disc protrusion has a high recurrence rate and is more prevalent in middle-aged and elderly individuals, with an increasing incidence among younger individuals. The intervertebral disc is a fibrocartilaginous structure situated between two adjacent lumbar vertebrae that serves to enhance spinal mobility, absorb shock, and safeguard the spinal cord. A tear in the annulus fibrosus, alongside the degeneration of the nucleus pulposus and the breakdown of the cartilage plate, play roles in the degeneration of the intervertebral disc, which can ultimately result in lumbar disc herniation.

Research has recognized ferroptosis as a possible pathogenic mechanism associated with lumbar disc herniation, although detailed mechanistic investigations remain scarce. Research indicates that rats suffering from lumbar degenerative disc disease exhibit reduced levels of the antioxidants GPX4 and FTH within the disc tissue. Conversely, the levels of cyclooxygenase (PTGS2) and ACSL4, both of which are integral to lipid metabolism, are elevated (174). These findings indicate the potential involvement of ferroptosis in the pathological mechanisms related to LDH. Furthermore, iron overload has been shown to exacerbate disc degeneration, ultimately contributing to herniation. In the course of the experiments, tert-butyl hydroperoxide (TBHP) was used to induce oxidative stress in annulus fibrosus cells (AFCs) and nucleus pulposus cells (NPCs). As the concentration of TBHP increased, the expression of FTH and GPX4 decreased, and the lipid ROS levels in the AFCs and NPCs increased. Characteristic features of ferroptosis, such as the crumpling of mitochondria and an increase in the mitochondrial membrane density, were observed at the mitochondrial level. Importantly, these alterations were attenuated by iron-induced death inhibitors (Fer-1 and DFO), further reinforcing the association between ferroptosis and the pathological mechanisms of LDH ( Figure 5 ) (174, 175).

Neovascularization is another characteristic of intervertebral disc protrusion. An experiment demonstrated the presence of neoangiogenesis in the herniated nucleus pulposus, which may contribute to tissue damage (176). Compared with patients with normal nucleus pulposus, patients with lumbar disc herniation presented higher haemoglobin concentrations in the disc nucleus pulposus, a higher quantity of dark iron particles following staining, and elevated expression levels of HO-1 (177). Increased concentrations of haemoglobin and haem may trigger ferroptosis, potentially through a mechanism linked to the Notch signaling pathway ( Figure 5 ) (177).

Atypical patterns of NPCs significantly contribute to the pathological progression of lumbar disc degeneration. Although these cells can produce components of the extracellular matrix, reductions in the levels of type II collagen and aggregated proteoglycans are often observed following disc injury (178). Furthermore, the iron overload and lipid peroxidation induced by TBHP in human NPCs can be significantly reversed by Fer-1 or the iron chelator DFO (176).

FPN is an important regulatory factor for cellular iron homeostasis. The overexpression of FPN can alleviate iron ion overload and ferroptosis in intervertebral disc cells. MTF1 eliminates intracellular iron overload by regulating FPN, thereby protecting intervertebral disc cells from ferroptosis ( Figure 5 ) (179). Chondrocytes are essential for maintaining the proper function of intervertebral discs. Research has shown a notable decrease in the chondrocyte population in degenerated intervertebral discs (180), with iron overload being a key contributing factor. In the chondrocytes of the iron overload model, the levels of GPX4 and SLC7A11 within the antioxidant system were lower, whereas lipid peroxidation levels, indicated by 4-HNE, were higher, and their mitochondria exhibited characteristics similar to ferroptosis (175). These findings suggest that the reduction in the number of chondrocytes within degenerated intervertebral discs could be linked to ferroptosis.

Furthermore, a notable rise in the expression levels of genes associated with autophagy, as well as a higher quantity of autophagic vacuoles and lysosomes, has been detected in degenerated intervertebral discs and the annulus fibrosus (181, 182). This finding suggests a potential link between the pathological process of LDH and autophagy. Both autophagy and ferroptosis contribute to the pathological process of disc degeneration. Notably, ferritin autophagy enhances autophagy and ferroptosis in NPC and AFC, whereas Fer-1 inhibits this process (174). Therefore, further investigation into the interaction network between ferroptosis and autophagy in bone diseases may deepen our understanding of their pathogenesis and provide novel insights for the treatment of such conditions.

In LDH, the inhibition of the DNA methyltransferase DNMT3B effectively prevents the onset of ferroptosis in NPCs and enhances cellular activity and mitochondrial function, suggesting a critical role in the regulation of iron homeostasis (183). Furthermore, TBHP can promote the accumulation of iron ions and induce ferroptosis by inhibiting the expression and nuclear export of the FPN. This process is regulated by the JNK/MTF1/FPN pathway, which constitutes a potential therapeutic target (179).

Osteosarcoma is a cancerous tumor of the bone characterized by high mortality rates, significant disability, and frequent metastasis and recurrence, primarily affecting the bones and lungs (184). The incidence rate is the highest among children and adolescents, with a higher rate in males than in females. OS often occurs near the growth plates of long bones (185). Clinically, the main treatment approach combines surgery with radiotherapy and chemotherapy. However, the effectiveness of traditional treatment methods for osteosarcoma is still limited, as the 5-year survival rate falls within the range of 60% to 70%. Moreover, significant progress in conventional therapies has been scarce over the past few years.

Ferroptosis has been recognized as a crucial element in the progression of tumors and the immune response, among other biological processes (186). Bavachin exerts its anticancer effects by triggering ferroptosis in osteosarcoma cells through multiple mechanisms. Among them, a reduction in matrix metalloproteinases (MMPs) leads to ferroptosis-like features in mitochondria (187). Furthermore, bavachin upregulated the expression of the transferrin receptor and DMT1 while downregulating the expression of FTL and FTH. These changes resulted in elevated intracellular Fe²⁺ levels and the downregulation of p-STAT3, SLC7A11, and GPX4 levels (57). Thus, bavachin clearly induces ferroptosis in osteosarcoma cells by modulating genes and proteins associated with cell death. Notably, the upregulation of P53 expression leads to lower expression levels of SLC7A11 and GPX4, promoting the accumulation of ROS and the lipid peroxidation product malondialdehyde (MDA), which in turn induces ferroptosis in osteosarcoma. This process is inhibited by ferroptosis inhibitors ( Figure 6 ) (187).

Tirapazamine (TPZ) is a novel anticancer drug that exerts its antitumour effect under hypoxic conditions (188). Under hypoxic conditions, SLC7A11 expression is reduced, whereas increases in MDA and Fe²⁺ levels increase ROS accumulation in osteosarcoma cells. This process triggers ferroptosis and suppresses the proliferation and metastasis of osteosarcoma (189). Cisplatin is a commonly used drug for treating osteosarcoma, but osteosarcoma cells can develop resistance to it, which reduces its therapeutic effect (190). Measurements of ferroptosis-associated proteins in osteosarcoma cells indicate that compared with normal cells, drug-resistant cells exhibit elevated GPX4 levels. Moreover, the use of ferroptosis inhibitors increases the sensitivity of these osteosarcoma cells to cisplatin, while diminishing the levels of ferroptosis-related proteins further enhances this sensitivity (191). The signaling pathway involving STAT3/Nrf2/GPX4 is integral to the resistance observed in osteosarcoma cells and may serve as a promising therapeutic target to improve the effectiveness of cisplatin against bone tumors ( Figure 6 ) (191).

Phenethyl isothiocyanate (PEITC) can cause cell cycle arrest and trigger apoptosis in tumor cells. It promotes ferroptosis in bone tumor cells by inducing oxidative stress, depleting GPX4, increasing ROS levels, and activating the MAPK signaling pathway (192, 193). The synthetic derivative of curcumin biphenyl-difluoroketone (EF24) has been reported to trigger cell apoptosis, restrain cell growth, and diminish metastatic capabilities (194, 195). Furthermore, EF24 induces ferroptosis in osteosarcoma cells by increasing the levels of lipid peroxides and intracellular iron ions. It also achieves this effect by increasing the expression of haem oxygenase 1 (HMOX1) and reducing the expression of GPX4 (196). This process can be counteracted with the application of ferroptosis inhibitors.

In recent advances in cancer therapy, it has been found that there may be an interaction between the molecular mechanisms involved in ferroptosis and cellular pyroptosis (197). Anti-tumor immune cells, such as T cells, can induce tumor cells to undergo pyroptosis while simultaneously increasing ROS to trigger ferroptosis, thereby exerting anti-tumor effects (198, 199). However, the molecular interactions between ferroptosis and pyroptosis remain unclear and warrant further investigation.

Induction of cellular ferroptosis significantly enhances the sensitivity of OS cells to both radiotherapy and chemotherapy. Although the specific epigenetic regulatory mechanisms remain incompletely understood, evidence suggests that epigenetic factors, including miRNAs and RNA methylation, may play a role in the therapeutic process by regulating key genes associated with ferroptosis, such as GPX4 and SLC7A11 (200).